Literature DB >> 19913246

Validation of the partin nomogram for prostate cancer in a national sample.

James B Yu1, Danil V Makarov, Richa Sharma, Richard E Peschel, Alan W Partin, Cary P Gross.   

Abstract

PURPOSE: The Partin tables are a nomogram that is widely used to discriminate prostate cancer pathological stages, given common preoperative clinical characteristics. The nomogram is based on patients undergoing radical prostatectomy at The Johns Hopkins Medical Institutions. We validated the Partin tables in a large, population based sample.
MATERIALS AND METHODS: The National Cancer Institute Surveillance, Epidemiology and End Results database was used to identify patients treated from 2004 to 2005 who underwent radical prostatectomy. The 2007 Partin tables were used to estimate the prevalence of positive lymph nodes, seminal vesicle invasion, extraprostatic extension and organ confined disease in men with prostate cancer in the database using clinical stage, preoperative prostate specific antigen and Gleason score. The discriminative ability of the tables was explored by constructing ROC curves.
RESULTS: We identified 11,185 men who underwent radical prostatectomy for prostate cancer in 2004 to 2005. The Partin tables discriminated well between patient groups at risk for positive lymph nodes and seminal vesicle invasion (AUC 0.77 and 0.74, respectively). The discrimination of extraprostatic extension and organ confined disease was more limited (AUC 0.62 and 0.68, respectively). The AUC for positive lymph nodes was 0.78 in white men, 0.73 in black men and 0.83 in Asian/Pacific Islander men (p = 0.17). The AUC for positive lymph nodes in men 61 years old or younger was 0.80 vs 0.74 in men older than 61 years (p = 0.03).
CONCLUSIONS: The Partin tables showed excellent discrimination for seminal vesicle invasion and positive lymph nodes. Discrimination of extraprostatic extension and organ confined disease was more limited. The Partin tables performed best in young men.

Entities:  

Mesh:

Year:  2010        PMID: 19913246     DOI: 10.1016/j.juro.2009.08.143

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

Review 1.  Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature.

Authors:  Giovanni Lughezzani; Alberto Briganti; Pierre I Karakiewicz; Michael W Kattan; Francesco Montorsi; Shahrokh F Shariat; Andrew J Vickers
Journal:  Eur Urol       Date:  2010-08-06       Impact factor: 20.096

2.  Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score.

Authors:  Ying Huang; Sumit Isharwal; Alexander Haese; Felix K H Chun; Danil V Makarov; Ziding Feng; Misop Han; Elizabeth Humphreys; Jonathan I Epstein; Alan W Partin; Robert W Veltri
Journal:  BJU Int       Date:  2010-09-28       Impact factor: 5.588

Review 3.  Biomarker research in prostate cancer--towards utility, not futility.

Authors:  Sheng Fei Oon; Stephen R Pennington; John M Fitzpatrick; R William G Watson
Journal:  Nat Rev Urol       Date:  2011-03       Impact factor: 14.432

Review 4.  Treatment of localized prostate cancer: when is active surveillance appropriate?

Authors:  Peter C Albertsen
Journal:  Nat Rev Clin Oncol       Date:  2010-05-04       Impact factor: 66.675

Review 5.  Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers.

Authors:  Matthew J Watson; Arvin K George; Mahir Maruf; Thomas P Frye; Akhil Muthigi; Michael Kongnyuy; Subin G Valayil; Peter A Pinto
Journal:  Future Oncol       Date:  2016-07-12       Impact factor: 3.404

6.  Temporal trends and predictors of pelvic lymph node dissection in open or minimally invasive radical prostatectomy.

Authors:  Andrew H Feifer; Elena B Elkin; William T Lowrance; Brian Denton; Lindsay Jacks; David S Yee; Jonathan A Coleman; Vincent P Laudone; Peter T Scardino; James A Eastham
Journal:  Cancer       Date:  2011-03-15       Impact factor: 6.860

7.  Development and Validation of Models to Predict Pathological Outcomes of Radical Prostatectomy in Regional and National Cohorts.

Authors:  Erkin Ötleş; Brian T Denton; Bo Qu; Adharsh Murali; Selin Merdan; Gregory B Auffenberg; Spencer C Hiller; Brian R Lane; Arvin K George; Karandeep Singh
Journal:  J Urol       Date:  2021-09-23       Impact factor: 7.450

8.  An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011.

Authors:  John B Eifler; Zhaoyang Feng; Brian M Lin; Michael T Partin; Elizabeth B Humphreys; Misop Han; Jonathan I Epstein; Patrick C Walsh; Bruce J Trock; Alan W Partin
Journal:  BJU Int       Date:  2012-07-26       Impact factor: 5.588

9.  ERG rearrangement as a novel marker for predicting the extra-prostatic extension of clinically localised prostate cancer.

Authors:  L I Lu; Hao Zhang; Jun Pang; Guo-Liang Hou; Min-Hua Lu; Xin Gao
Journal:  Oncol Lett       Date:  2016-02-25       Impact factor: 2.967

10.  Prostate cancer cell phenotypes based on AGR2 and CD10 expression.

Authors:  Melissa E Ho; Sue-Ing Quek; Lawrence D True; Colm Morrissey; Eva Corey; Robert L Vessella; Ruth Dumpit; Peter S Nelson; Erin L Maresh; Vei Mah; Mohammed Alavi; Sara R Kim; Lora Bagryanova; Steve Horvath; David Chia; Lee Goodglick; Alvin Y Liu
Journal:  Mod Pathol       Date:  2013-01-25       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.